- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00934817
Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg
An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M 1mg/500mg and 2mg/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Subjects
The pharmacokinetics of glimepiride and metformin HCl will be compared after single dose intake of both combinations in order to answer the following questions:
- Is Amaryl-M 1/500 mg (Test tablet) proportional to Amaryl-M 2/500 mg tablet with regard to the glimepiride component?
- Is Amaryl-M 1/500 mg (Test tablet) tolerable comparing with Amaryl-M 2/500 mg?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
16 subjects were randomized to each of 2 sequence groups which have different treatment order of the study drug in each period.
Only healthy volunteers had screening tests such as medical inquiry, physical examination, clinical laboratory test, etc. within 4 weeks (-28d ~ -1d) prior to drug administration (1d) and those determined eligible for this study were selected and randomized between screening and 1 day prior to the first administration of study medication (-1d). Then, the subjects were admitted to the clinical research center of Seoul National University Hospital by 9 p.m. of -1d and then, they were not allowed to take anything except water.
After one week of washout period, subjects went on to the second phase of treatment period and were administered according to the treatment order in a crossover way. For the subjects who completed the study, post-study visit tests were performed after a designated time had passed.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: Between 19 to 45 years of age, inclusive (age based on the date to give the informed consent)
- Ideal body weight (Broca index): between 50 to 90 kg, inclusive, and within ±20 % of Ideal Body Weight, [(Height in cm-100)×0.9]
- Subjects who are appropriate to participate in this study judged from clinical laboratory and physical examinations taken within 4weeks prior to the start of study
- Subjects who are able to abstain from caffeine or caffeine-containing products (e.g., coffee, cola, tea, chocolate), grapefruit and grapefruit containing products, alcohol and smoking within 7 days before dosing and during the hospitalization
- Subjects who give their informed consent voluntarily to participate in the study
Exclusion Criteria:
- History of allergies including drug allergy, except untreated, asymptomatic, seasonal allergies at the time of dosing
- Use any medication not considered acceptable by the clinical investigator during the last 10 days period before the start day of the study
- Use of any inducer or inhibitors of metabolizing enzymes during the last 28 days before the start day of the study.
- History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease
- History of a significant surgical resection of gastrointestinal tract except appendectomy
- Abnormal clinical laboratory findings, especially for AST or ALT > 1.25 fold, total bilirubin > 1.5 fold of upper normal level
- Pregnant or lactating woman or woman of childbearing potential without medically acceptable birth control during the study
- Evidence of alcohol abuse (defined as regular alcohol intake that exceeds 24 oz [675 ml] of beer, 12 oz [340 ml] of wine or 160 ml of soju or 3 oz [85 ml] hard liquor per day [e.g., brandy, whiskey, gin]) or drug abuse
- Heavy smokers (> 10 cigarettes per day), or can't quit smoking during hospitalization
- Participation in clinical trials of any drug within 3 months prior to the start of study
- Donation of 200ml of whole blood within 4 weeks or 400ml within 12 weeks prior to the start of study
- Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or HIV antibody
- Judged to be inappropriate for the study by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TR sequential group
Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
|
single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
Other Names:
single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
Other Names:
|
Active Comparator: RT sequential group
Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
|
single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
Other Names:
single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma drug concentrations of glimepiride and metformin, PK parameters: AUCt, AUCinf, Cmax, Tmax, T1/2
Time Frame: pre-dose (= 1d 0h), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 30 hrs after drug administration
|
pre-dose (= 1d 0h), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 30 hrs after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Physical examination, clinical laboratory tests
Time Frame: Screening, 2 day, 9 day, 13-15 day
|
Screening, 2 day, 9 day, 13-15 day
|
Vital sign
Time Frame: screening, 1 day, 2 day, 8 day, 9 day, 13-15 day
|
screening, 1 day, 2 day, 8 day, 9 day, 13-15 day
|
Adverse event
Time Frame: 1 day, 2 day, 8 day, 9 day, 13-15 day
|
1 day, 2 day, 8 day, 9 day, 13-15 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: In-Jin Jang, Professor, Seoul National University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLIME_L_02279
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Amaryl-M 2/500 mg
-
Handok Inc.Completed
-
Canadian Heart Research CentreGlaxoSmithKlineCompletedType 2 Diabetes MellitusCanada
-
CicloMed LLCCmed Clinical ServicesCompletedAdvanced Solid TumorsUnited States
-
Merck KGaA, Darmstadt, GermanyCompletedNon-Small Cell Lung Cancer (NSCLC)Germany
-
Millennium Pharmaceuticals, Inc.CompletedMyelodysplastic Syndromes | Leukemia, Myeloid, AcuteJapan, Taiwan, Korea, Republic of
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedAdvanced Solid TumorUnited States
-
HighField Biopharmaceuticals CorporationRecruiting
-
R-PharmTerminated
-
Eisai Inc.CompletedSoft Tissue SarcomaUnited States, France, United Kingdom, Germany, Spain, Belgium, Argentina, Israel, Poland, Romania, Korea, Republic of, Canada, Netherlands, Australia, New Zealand, Singapore, Brazil, Russian Federation, Austria, Thailand, Italy, ... and more
-
Merck Sharp & Dohme LLCCompletedNon-small Cell Lung CancerUnited States, Australia, France, Germany, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, United Kingdom